Dec 2 (Reuters) - Biopharmaceutical company XenoPort Inc said its treatment to reduce symptoms of acid reflux failed to meet the main goal in a mid-stage study, sending its shares down 34 percent before the bell.
Dec 2 (Reuters) - Biopharmaceutical company XenoPort Inc said its treatment to reduce symptoms of acid reflux failed to meet the main goal in a mid-stage study, sending its shares down 34 percent before the bell.
